Matches in Wikidata for { <http://www.wikidata.org/entity/Q83831101> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q83831101 description "2011 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված" @default.
- Q83831101 description "artículu científicu espublizáu n'abril de 2011" @default.
- Q83831101 description "scientific article published on 11 April 2011" @default.
- Q83831101 description "wetenschappelijk artikel" @default.
- Q83831101 description "наукова стаття, опублікована у квітні 2011" @default.
- Q83831101 name "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 name "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 type Item @default.
- Q83831101 label "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 label "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 prefLabel "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 prefLabel "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 P1433 Q83831101-D092FBE6-E923-43FC-92F7-F8DA17A529ED @default.
- Q83831101 P1476 Q83831101-7AD79EB1-DB7B-4667-8902-22D34E8A4663 @default.
- Q83831101 P2093 Q83831101-05995001-8AAB-49B5-970C-16EEAAA9809D @default.
- Q83831101 P2093 Q83831101-1C3129FE-7FFA-481B-8265-7D9552F010C6 @default.
- Q83831101 P2093 Q83831101-2157DF77-797D-4727-8E13-AE8B613E4D36 @default.
- Q83831101 P2093 Q83831101-3D9F845C-2053-4A24-8FF7-7F2EC47AE933 @default.
- Q83831101 P2093 Q83831101-435E00BA-A096-49E7-A61B-72B99C14EE83 @default.
- Q83831101 P2093 Q83831101-563BDE5F-B19E-40B8-ADEA-7A7341AD77CB @default.
- Q83831101 P2093 Q83831101-6C3D6ED6-4390-4BCA-BA11-E1D51BC90305 @default.
- Q83831101 P2093 Q83831101-6E0465A6-1FBF-47AD-887B-3DC66596A2BD @default.
- Q83831101 P2093 Q83831101-7375FD14-EC82-4FE4-9EED-1613541AE5E4 @default.
- Q83831101 P2093 Q83831101-7ABAE3A3-27B4-4702-9B36-B8EA5677706F @default.
- Q83831101 P2093 Q83831101-7B77370E-988B-4804-A880-EA4EE4945419 @default.
- Q83831101 P2093 Q83831101-A1493AD9-1F9F-4396-9018-FF44C18F25B0 @default.
- Q83831101 P2093 Q83831101-AA8D60BA-3A5C-4821-BC82-6390F6DCA7E0 @default.
- Q83831101 P2093 Q83831101-CAD9BF5E-9613-4006-B5FA-1D37981F7F82 @default.
- Q83831101 P2093 Q83831101-D6E11CE1-458E-43D1-84EC-A3D0FF1507C2 @default.
- Q83831101 P2093 Q83831101-EF4C41AF-4612-45BD-A5AE-B475936FCB7B @default.
- Q83831101 P304 Q83831101-F5126187-7999-4294-8420-FBD8EBE0D49B @default.
- Q83831101 P31 Q83831101-4D4547C7-2350-4DB3-B08A-3065A3734718 @default.
- Q83831101 P356 Q83831101-544187D0-7FE2-460C-AE97-8CC018513149 @default.
- Q83831101 P433 Q83831101-AB0D494C-511F-4034-8F58-6B39472DC7A4 @default.
- Q83831101 P478 Q83831101-CCFA4978-07CE-41B6-B1F4-2DA3E401D018 @default.
- Q83831101 P577 Q83831101-9923E57E-3BC5-42BC-8E1D-3379119EB0A1 @default.
- Q83831101 P698 Q83831101-57D5D062-337E-4D46-B311-164495B0C178 @default.
- Q83831101 P921 Q83831101-3FE0EF10-97B5-47E8-8281-4D27A94ACC54 @default.
- Q83831101 P921 Q83831101-4546EE82-73F8-49E5-A143-28B067CA14C0 @default.
- Q83831101 P921 Q83831101-707FDEAD-8752-423B-8BCF-4D9E07F25F25 @default.
- Q83831101 P356 JCO.2010.32.8815 @default.
- Q83831101 P698 21483004 @default.
- Q83831101 P1433 Q400292 @default.
- Q83831101 P1476 "Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer" @default.
- Q83831101 P2093 "Anthony A Meluch" @default.
- Q83831101 P2093 "Axel Heidenreich" @default.
- Q83831101 P2093 "Brian Henick" @default.
- Q83831101 P2093 "David Waterhouse" @default.
- Q83831101 P2093 "Dean J Ruether" @default.
- Q83831101 P2093 "Glenn Heller" @default.
- Q83831101 P2093 "Howard I Scher" @default.
- Q83831101 P2093 "Kim Chi" @default.
- Q83831101 P2093 "Luis Chu" @default.
- Q83831101 P2093 "Luke T Nordquist" @default.
- Q83831101 P2093 "Peter Albers" @default.
- Q83831101 P2093 "Peter J Rosen" @default.
- Q83831101 P2093 "Peter M Venner" @default.
- Q83831101 P2093 "Ronald de Wit" @default.
- Q83831101 P2093 "William R Berry" @default.
- Q83831101 P2093 "Xiaoyu Jia" @default.
- Q83831101 P304 "2191-2198" @default.
- Q83831101 P31 Q13442814 @default.
- Q83831101 P356 "10.1200/JCO.2010.32.8815" @default.
- Q83831101 P433 "16" @default.
- Q83831101 P478 "29" @default.
- Q83831101 P577 "2011-04-11T00:00:00Z" @default.
- Q83831101 P698 "21483004" @default.
- Q83831101 P921 Q181257 @default.
- Q83831101 P921 Q420436 @default.
- Q83831101 P921 Q42824827 @default.